Review
Nature Reviews Cancer 6, 117-129 (February 2006) | doi:10.1038/nrc1800
There is a Corrigendum (1 March 2006) associated with this article.
Focus on: Biomarkers
Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy
Meyling H. Cheok1 & William E. Evans2 About the authors
Abstract
The use of combination chemotherapy to cure acute lymphoblastic leukaemia (ALL) in children emerged in the 1980s as a paradigm for curing any disseminated cancer, and many of the therapeutic principles were subsequently applied to the treatment of other disseminated human cancers. Similarly, elucidation of the pharmacogenomics of ALL and its translation into new chemotherapeutic approaches might serve as a model for optimizing the treatment of other human cancers. Germline polymorphisms and gene-expression patterns in ALL cells have been linked to the toxicity and efficacy of chemotherapy for ALL and are beginning to emerge as useful clinical diagnostics.
- View At a Glance
Author affiliations
- St. Jude Children's Research Hospital, Department of Pharmaceutical Sciences, 332 North Lauderdale Street, Memphis, Tennessee 38105, USA.
- The University of Tennessee, Memphis, Tennessee 38105, USA.
Correspondence to: William E. Evans2 Email: william.evans@stjude.org
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Gazing into a crystal ball?cancer therapy in the post-genomic eraNature Medicine News and Views (01 Mar 2001)
RESEARCH
Mechanistic mathematical modelling of mercaptopurine effects on cell cycle of human acute lymphoblastic leukaemia cellsBritish Journal of Cancer Original Article
Karyotypic abnormalities create discordance of germline genotype and cancer cell phenotypesNature Genetics Letter (01 Aug 2005)
See all 27 matches for Research